NeuroSense Therapeutics (NRSN) Institutional Ownership $1.27 +0.02 (+1.60%) (As of 11/1/2024 ET) Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for NeuroSense Therapeutics (NASDAQ:NRSN)CurrentInstitutional OwnershipPercentage1.04%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$1.81MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$428.84K Get NRSN Insider Trade Alerts Want to know when executives and insiders are buying or selling NeuroSense Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. NeuroSense Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024Armistice Capital LLC1,584,000$1.77M0.0%N/A11.591% 8/12/2024XTX Topco Ltd32,650$37K0.0%N/A0.239% 11/15/2023Armistice Capital LLC662,000$470K0.0%-47.7%6.051% 5/11/2023 Meitav Investment House Ltd.95,000$193K0.0%N/A0.868% (Data available from 1/1/2016 forward) NRSN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NRSN shares? During the previous two years, the following institutional investors and hedge funds held shares of NeuroSense Therapeutics shares: Armistice Capital LLC ($1.77M), and Meitav Investment House Ltd. ($193K), XTX Topco Ltd ($37K).Learn more on NRSN's institutional investors. What percentage of NeuroSense Therapeutics stock is owned by institutional investors? 1.04% of NeuroSense Therapeutics stock is owned by institutional investors. Learn more on NRSN's institutional investor holdings. Which institutional investors have been buying NeuroSense Therapeutics stock? The following institutional investors have purchased NeuroSense Therapeutics stock in the last 24 months: Armistice Capital LLC ($1.58M), Meitav Investment House Ltd. ($95K), and XTX Topco Ltd ($32.65K). How much institutional buying is happening at NeuroSense Therapeutics? Institutional investors have bought a total of 1,711,650 shares in the last 24 months. This purchase volume represents approximately $1.97M in transactions. Which NeuroSense Therapeutics major shareholders have been selling company stock? The following institutional investors have sold NeuroSense Therapeutics stock in the last 24 months: Armistice Capital LLC ($604K). How much institutional selling is happening at NeuroSense Therapeutics? Institutional investors have sold a total of 604,000 shares in the last 24 months. This volume of shares sold represents approximately $428.84K in transactions. Related Companies ALXO Institutional Ownership VRCA Institutional Ownership SPRO Institutional Ownership CTXR Institutional Ownership RAPT Institutional Ownership ONCO Institutional Ownership SYRS Institutional Ownership VHAQ Institutional Ownership EPRX Institutional Ownership CNTB Institutional Ownership This page (NASDAQ:NRSN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
